Does Medicare Cover Ketamine Tablets? What Patients Should Know

The Short Answer: Medicare Rarely Covers Oral Ketamine Tablets

If you're asking whether Medicare covers oral ketamine tablets prescribed for depression, treatment-resistant depression (TRD), or chronic pain, the practical answer for most beneficiaries is no — not through traditional Medicare, and not through most Medicare Advantage plans either.

The core reason: oral ketamine tablets used for psychiatric purposes are typically compounded medications made by specialized pharmacies. They are not FDA-approved drugs for those indications. Medicare Part D, which covers prescription drugs, generally excludes compounded medications. Part B, which covers certain outpatient drugs given in clinical settings, doesn't apply to tablets taken at home.

That said, coverage rules are complex and vary by plan. This guide explains the underlying reasons, how a different form of ketamine — Spravato (esketamine nasal spray) — does receive Medicare coverage, and what questions to bring to your prescriber or pharmacist if you're weighing your options.

Why Medicare Doesn't Typically Cover Oral Ketamine Tablets

Understanding the coverage gap starts with how Medicare evaluates drug coverage eligibility.

The off-label and compounding issue. Oral ketamine tablets for depression or TRD are almost always compounded — meaning a compounding pharmacy formulates them specifically for a patient based on a prescriber's instructions. Ketamine itself has FDA approval as an anesthetic administered by injection in controlled settings, but oral tablet forms for psychiatric use are not FDA-approved products. Medicare Part D plans are required to cover FDA-approved drugs listed on their formulary. Compounded medications do not appear on any plan's formulary and generally fall outside what Part D will pay for. According to CMS guidance on compounded drugs, Part D cannot cover most compounded preparations, with narrow exceptions that rarely apply to ketamine.

The home-use problem for Part B. Medicare Part B can cover certain drugs — but only when they are FDA-approved, medically necessary, and administered by or under the direct supervision of a physician in a qualifying outpatient setting. Oral tablets taken at home do not meet that administration standard, regardless of what they contain.

Schedule III controlled substance classification. Ketamine is classified as a Schedule III controlled substance by the DEA. While Schedule III status doesn't directly disqualify a drug from Medicare coverage, it does mean prescribing, dispensing, and prescriber registration carry additional documentation requirements that affect how compounding pharmacies and prescribers handle these orders — and adds one more layer of complexity for insurers reviewing claims.

How Spravato (Esketamine) Is Different for Medicare Coverage

Spravato is worth understanding in detail because it is a form of ketamine that does receive Medicare coverage — and knowing exactly why helps clarify where oral tablets fall short.

Spravato (esketamine) received FDA approval in 2019 for treatment-resistant depression and, later, for major depressive disorder with suicidal ideation. It is a nasal spray, not an oral tablet, and it is classified as an FDA-approved drug — not a compounded preparation. Because it is FDA-approved, it can appear under Medicare Part B as an outpatient drug administered in a certified healthcare setting.

Critically, Spravato is subject to a Risk Evaluation and Mitigation Strategy (REMS) that requires patients to receive each dose in a certified healthcare facility and be monitored for at least two hours afterward. They cannot take it home. That in-clinic administration requirement is what places it under Part B — a drug administered by or under the supervision of a provider in an outpatient setting. Part B cost-sharing (typically 20% coinsurance after the deductible) applies, meaning it is not free, but it is covered for qualifying patients.

Oral ketamine tablets, by contrast, are taken at home without clinical supervision. That difference in delivery method — combined with the lack of FDA approval for oral psychiatric use — places them entirely outside the Medicare coverage structure that Spravato inhabits.

If you're weighing these options, the differences in how ketamine is absorbed by route may also inform your conversation with a clinician. The two forms behave differently in the body, which affects both clinical outcomes and the regulatory treatment they receive.

Does Medicare Advantage (Part C) Change Anything?

Medicare Advantage plans are required to cover everything that original Medicare covers, but they are run by private insurers and can offer supplemental benefits beyond the standard Medicare baseline. Some plans have broader formularies or supplemental drug benefits.

However, the underlying restriction on compounded medications doesn't disappear in Medicare Advantage. Advantage plans that include drug coverage (MA-PD plans) still generally follow CMS rules about compounded drugs under Part D-style coverage. The fundamental issue — that oral ketamine tablets for psychiatric use are compounded and off-label — doesn't change with a different plan structure.

Some Medicare Advantage plans include supplemental health-related spending accounts or OTC allowances, but these are typically designed for over-the-counter products, not Schedule III prescription compounds. The practical impact on ketamine tablet costs is likely minimal to none in most situations.

If you have a Medicare Advantage plan and want to check specifically for your situation, request a written Evidence of Coverage (EOC) document and call the plan's pharmacy benefits line — not just general customer service. Ask specifically whether compounded Schedule III controlled substances are covered under any benefit category, and whether any supplemental benefits apply to prescription compound costs.

What Oral Ketamine Tablets Cost Without Medicare Coverage

Because Medicare rarely covers oral ketamine tablets, most beneficiaries who pursue this route pay out of pocket. Costs vary depending on the compounding pharmacy, the dose strength, and how frequently the medication is taken.

A monthly supply of compounded oral ketamine tablets can range from roughly $150 to $500 or more, depending on those variables. This does not include the cost of prescriber visits, required monitoring, or ancillary supplies. The prescribing visit — often with a psychiatrist, pain specialist, or other specialist — may or may not be covered separately depending on your Medicare plan and the documented reason for the visit.

For a more detailed breakdown of what to expect, see the guide to oral ketamine tablets cost without insurance. It covers common pricing structures, what compounding pharmacies typically charge, and factors that affect the final number including dose and dosing frequency.

Understanding how first-pass metabolism affects oral ketamine absorption may also help you have a more informed conversation about dosing and why cost-per-dose can vary by formulation — this is particularly relevant when comparing tablet and sublingual options.

Questions to Bring to Your Prescriber and Pharmacist

Coverage is plan-specific and situation-specific in ways that general guidance can't resolve. The most productive step is a direct conversation with both your prescriber and, separately, a compounding pharmacy that handles controlled substances.

Useful questions to ask your prescriber:

• Is there an FDA-approved treatment for my diagnosis that Medicare is more likely to cover?
• If I pursue compounded oral tablets, can you document the medical necessity in a way that supports an insurance review or appeal?
• What is your experience helping Medicare patients access ketamine therapy, and what has been most effective?

Useful questions to ask the compounding pharmacy:

• What is the cash price for the prescription as written, including all dispensing fees?
• Do you offer self-pay pricing programs or work with any patient assistance organizations?
• Will you submit a claim to Medicare on my behalf, so I have documentation for an appeal if needed?

You can also contact your local State Health Insurance Assistance Program (SHIP) for free, personalized Medicare counseling. SHIP counselors can help you understand your specific benefits and navigate coverage questions at no cost.

Regulatory Context in 2026

Federal policy around ketamine prescribing, compounding, and access has continued to evolve. DEA telemedicine rules affecting how controlled substances can be prescribed via telehealth have been modified since the pandemic-era flexibilities, which may affect how some patients access oral ketamine prescriptions. None of these regulatory changes directly resolve the Medicare coverage gap for compounded oral ketamine tablets, but they can affect whether and how a prescription is obtainable in the first place — especially for patients in rural areas who rely on telehealth access.

If an FDA-approved oral ketamine tablet were to reach the market for a psychiatric indication in the future, it could potentially appear on Part D formularies — but that would depend on individual plans choosing to include it, and cost-sharing would still apply. As of mid-2026, no such product is commercially available. You may also find it useful to understand how generic versus brand-name tablet formulations differ, even though Medicare coverage considerations apply similarly to both compounded forms.